Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- Takeda Aims at Top Share for DPP-4 Inhibitors with Nesina
June 7, 2010
- Asahi Kasei Pharma: Sales Down 8.2% to ¥56.0 Bil.
June 7, 2010
- Revlimid, Torisel Recommended for Approval
June 7, 2010
- Mark Smith Appointed President of Merck Serono in Japan
June 7, 2010
- Yakult: Campto Patent Expiration Hits Pharm. Business
June 7, 2010
- Industry Should Generate Visible Benefits of New Premium System: Dr Suzuki of JMA
June 7, 2010
- Ethical Drugs' Sales Up 4.7% in FY2009: Crecon
June 7, 2010
- Fuso: Pharm. Sales Up 1.5% Driven by Dialysis-Related Products
June 7, 2010
- AZ, J&J to Jointly Develop CAPS System in Japan
June 7, 2010
- Average Operating Profit Rate Up to 0.57% for Top-4 Wholesalers
June 7, 2010
- ASKA: Large Drop in Profits Despite 17.6% Increase in Sales
June 7, 2010
- Takara Bio: Sales Up 2.2% to ¥19,325 Mil.
June 7, 2010
- Toho Aims at Reducing Yakkasa by 1.5-2 Points
June 7, 2010
- Seikagaku: Artz Props Up Sales 1.5% to ¥27,617 Mil.
June 7, 2010
- A Coming of Age
Philip Carrigan
Partner, Optia Partners
philip@optiapartners.com
June 7, 2010
- Ajinomoto: Pharm. Sales Down 3.7% to ¥82.6 Bil.
June 7, 2010
- Wakamoto: Sales Down 3.0% to ¥9,776 Mil.
June 7, 2010
- Korosho Asks Companies to Develop 108 Drugs & Indications
June 7, 2010
- JCR Pharmaceuticals: Sales Up 19.1% to ¥14,387 Mil.
June 7, 2010
- Otsuka Discontinues Development of Amsilarotene
June 7, 2010
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…